Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Biotech
Regeneron signs Mammoth gene editing deal worth $100M upfront
Regeneron is signing another major deal in gene editing—and, this time, it’s Mammoth.
Annalee Armstrong
Apr 25, 2024 8:49am
Regeneron builds new venture arm with $500M commitment
Apr 15, 2024 9:58am
FDA's Richard Pazdur explains confirmatory trial rejection, more
Apr 8, 2024 6:00am
AACR: Regeneron's multiple myeloma drug shows staying power
Apr 7, 2024 4:00pm
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Mar 29, 2024 5:00am
FDA blocks approval of Regeneron's blood cancer drug
Mar 25, 2024 9:25pm